A61K 39 - Medicinal preparations containing antigens or antibodies

Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
11/2006
11/16/2006	US20060257420 Methods of preparation and composition of peptide constructs useful for treatment of autoimmune and transplant related host versus graft conditions
11/16/2006	US20060257419 Bordetella pertussis antigen consisting lipopolysaccharide, pertusis toxin, filamentous hemagglutinin, pertactin or abosrbed to alum; interleukin-12 ; enhances cell-mediated immunity in a host
11/16/2006	US20060257418 Vaccine
11/16/2006	US20060257417 Vaccine antigens of Moraxella
11/16/2006	US20060257416 Materials and methods for improved vaccination
11/16/2006	US20060257415 Adjuvants
11/16/2006	US20060257414 Mycoplasma gallisepticum formulation
11/16/2006	US20060257413 Novel immunogenic compositions for the prevention and treatment of meningococcal disease
11/16/2006	US20060257412 Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
11/16/2006	US20060257411 Compositions and methods for modulating cells via CD14 and toll-like receptor 4 signaling pathway
11/16/2006	US20060257410 Inhibit binding of a competitor antibody to CCX-CKR2 (chemokine receptors), competitor antibody comprises the complementarity determining region (CDR); cancer, angiogenesis and arthritis
11/16/2006	US20060257409 Breast Specific Genes and Proteins
11/16/2006	US20060257408 Method for influencing kinase pathways with IL-22
11/16/2006	US20060257407 Anti-IL-6 antibodies, compositions, methods and uses
11/16/2006	US20060257406 Immunoglobulin variable domain; tumor necrosis factor; competitve binding; surface plasmon resonance
11/16/2006	US20060257405 Diagnostics and therapeutics for diseases associated with aryl hydrocarbon receptor (ahr)
11/16/2006	US20060257404 Modulators of the P2Y10 receptor useful in altering T lymphocyte function
11/16/2006	US20060257403 Methods for treating and preventing fibrosis
11/16/2006	US20060257402 Use of soluble cd164 in inflammatory and/or autoimmune disorders
11/16/2006	US20060257401 Sensitizing cells for apoptosis by selectively blocking cytokines
11/16/2006	US20060257400 Combination therapy
11/16/2006	US20060257399 Mixture comprising n-glycan modified antibodies exhibiting increased antibody-dependent cellular cytoxicity (ADCC); targeted destruction of tumor cells
11/16/2006	US20060257398 humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker; B-cell malignancies and autoimmune diseases
11/16/2006	US20060257397 Human binding molecule against CD1A
11/16/2006	US20060257396 Abeta antibodies for use in improving cognition
11/16/2006	US20060257395 System and method for magnifying a humoral immune response
11/16/2006	US20060257394 Modified antibody fab fragments
11/16/2006	US20060257393 Method for protecting thiol group of protein
11/16/2006	US20060257390 Catheter Composition and Uses Thereof
11/16/2006	US20060257376 Improves the efficiency of targeting cells to the bone marrow, and/or to modulate hematopoietic progenitor cell function
11/16/2006	US20060257374 Use of bdellovibrionaceae as an antimicrobial agent
11/16/2006	US20060257358 Suspension of calcium phosphate particulates for local delivery of therapeutic agents
11/16/2006	US20060257356 Administering EBV peptide epitope for eliciting an immune response against EBV; therapy and prophylaxis of lymphoproliferative disorders
11/16/2006	US20060257317 Combination therapy in the treatment of cancer
11/16/2006	CA2608316A1 Vaccine composition
11/16/2006	CA2608195A1 Nebulization of monoclonal antibodies for treating pulmonary diseases
11/16/2006	CA2608058A1 Host cell specific binding molecules capable of neutralizing viruses and uses thereof
11/16/2006	CA2607868A1 Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease
11/16/2006	CA2607569A1 Compositions and methods for modulating cells via cd14 and toll-like receptor 4 signaling pathway
11/16/2006	CA2607281A1 Anti-cd19 antibody therapy for autoimmune disease
11/16/2006	CA2607213A1 Use of nk cell inhibition to facilitate persistence of engrafted mhc- i negative cells
11/16/2006	CA2607176A1 Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
11/16/2006	CA2607170A1 Method for the isolation of spiroplasma in mammals
11/16/2006	CA2607082A1 Immunoglobulin fraction and process therefor
11/16/2006	CA2607044A1 Cardiovascular disease therapies
11/16/2006	CA2606890A1 Immunogens for meningitidis-a vaccines
11/16/2006	CA2606871A1 Use of native peptides and their optimized derivatives for vaccination
11/16/2006	CA2606778A1 Vascular disease therapies
11/16/2006	CA2606287A1 Peptide
11/16/2006	CA2605015A1 Compositions and assays to detect influenza virus a and b nucleic acids
11/16/2006	CA2605006A1 Melanoma-associated endogenous retrovirus (merv) derived peptide sequences and their therapeutic/ diagnostic use
11/15/2006	EP1722230A2 Method for detection of a disease-specific combinatorial molecular pattern motif in a tissue sample of a patient's skin
11/15/2006	EP1721987A1 Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
11/15/2006	EP1721982A1 Chimeric lyssavirus nucleic acids and polypeptides
11/15/2006	EP1721981A1 Recombinant varicella-zoster virus
11/15/2006	EP1721978A1 Nucleotide sequences coding for alpha chain variable regions in human lymphocyte receptors and applications thereof
11/15/2006	EP1721965A1 Method for the preparation and use of protozoan cultures
11/15/2006	EP1721909A1 Growth factor mutants with altered biological attributes
11/15/2006	EP1721618A2 Proteosome influenza vaccine composition
11/15/2006	EP1721158A2 Modulators of angiogenesis
11/15/2006	EP1721157A1 Use of tweak modulators and inhibitors for the treatment of neurological conditions
11/15/2006	EP1721003A1 Diagnostics and therapeutics for diseases associated with kallikrein 5 (klk5)
11/15/2006	EP1720996A1 Fusion proteins containing recombinant cytotoxic rnases
11/15/2006	EP1720910A2 Method and composition for angiogenesis inhibition
11/15/2006	EP1720909A2 Anti-abeta antibody
11/15/2006	EP1720908A2 Super-humanized antibodies against respiratory syncytial virus
11/15/2006	EP1720905A2 Methods for generating immunity to antigen
11/15/2006	EP1720900A1 Fusion proteins comprising modified allergens of the ns-ltps family, use thereof and pharmaceutical compositions comprising the same
11/15/2006	EP1720899A2 Multimerised hiv fusion inhibitors
11/15/2006	EP1720575A2 Therapeutic and diagnostic conjugates for use with multispecific antibodies
11/15/2006	EP1720574A1 Method of treating abnormal cell growth using c-met and-tor inhibitors
11/15/2006	EP1720573A2 Methods and compositions for treating il-13 related pathologies
11/15/2006	EP1720572A1 Monovalent ligand of the fcalphari receptor as an anti-inflammatory agent
11/15/2006	EP1720571A2 Method of treating hemolytic disease
11/15/2006	EP1720570A2 Treatment of dengue hemorrhagic fever
11/15/2006	EP1720569A1 Target for b-cell disorders
11/15/2006	EP1720568A2 Immunostimulatory viral rna oligonucleotides
11/15/2006	EP1720567A2 Composition and method for the treatment of carcinoma
11/15/2006	EP1720566A2 A vaccine composition comprising an immunoadjuvant compound consisting of a rho gtpase family activator
11/15/2006	EP1720565A1 Co-encapsulated wt1 polypeptide and immunostimulant microsphere formulations and methods thereof
11/15/2006	EP1720530A2 Screening method for emulators of neural activity and digestive system using gpr35
11/15/2006	EP1720525A1 Powdered compositions of sensitive active materials in an at least partially amorphous state
11/15/2006	EP1720519A1 Lyophilization method to improve excipient crystallization
11/15/2006	EP1720410A1 Compositions and methods for the treatment and clinical remission of psoriasis
11/15/2006	EP1720405A2 Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
11/15/2006	EP1547612A4 Medicinal agent and method for curing erectile dysfunction
11/15/2006	EP1410040B1 Method for identifying substances which modulate interleukin 4 (il-4) signaling
11/15/2006	EP1407014B1 Screening method for attenuating or virulence defective microbial cells
11/15/2006	EP1286696B1 Outer membrane vesicle vaccine against disease caused by neisseria meningitidis serogroup a and process for the production thereof
11/15/2006	EP1283869B1 Novel bee venom polypeptides and methods of use thereof
11/15/2006	EP1278768B1 Method for identifying helicobacter antigens
11/15/2006	EP1222281B1 Immunoligically significant herpes simplex virus antigens
11/15/2006	EP1208214B1 Genetically engineered bleb vaccine
11/15/2006	EP1198560B1 Mammalian adhesion protease
11/15/2006	EP1064372B1 Compounds and methods for therapy and diagnosis of lung cancer
11/15/2006	EP1054950B1 Hiv chemokines
11/15/2006	EP1009430B1 Oil in water emulsion vaccines against Hepatitis B
11/15/2006	CN1863906A Tolerizing allografts of pluripotent stem cells
11/15/2006	CN1863556A Compositions and methods for treating coagulation related disorders
11/15/2006	CN1863555A Compositions and methods for manipulating levels antigen-specific antibodies in a mammal

1 ... 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 ... 1823